


VIAL, H. et al.

Serial No. **unknown**

US National Phase of PCT/GB00/02122

R_c represents R₃ or U, U representing the group of formula



R₁, R₂, R₃ and Z being as defined in claim 1,

it being understood that R_b = T, if R_c = R₃ and R_d = R₂; R_d = P, if R_c = R₃ and R_b = R₁; and R_c = U, if R_b = R₁ and R_d = R₂.

in combination with a pharmaceutically inert vehicle.

21. (Amended) Pharmaceutical compositions according to claim 19, characterized in this that they can be administered by oral route, by injectable route, or also by rectal route.

REMARKS

The claims have been amended to delete improper multiple dependencies.

The Office is requested to note the pending claims are separately attached as an English translation of the annexes to the IPER.

An early and favorable Action on the merits is requested.


VIAL, H. et al.

Serial No. **unknown**

US National Phase of PCT/GB00/02122

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 
B. J. Sadoff
Reg. No. 36,663

BJS:ecb
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

605020 9847000

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION

Page 1, before the first line, insert as a separate paragraph:


--This application is the US National Phase of International PCT/GB00/02122
filed 21 June 1999, which designated the US.--

IN THE CLAIMS


5. (Amended) Precursors according to [any one of] claim[s] 2 [to 4], characterized in that \underline{R}_1 is a methyl radical and \underline{R}'_1 is either a hydrogen atom, or a methyl radical, and \underline{W} is a chlorine atom.

6. (Amended) Precursors according to [any one of] claim[s] 2[to 5], characterized in that they are chosen from N, N'-dimethyl-N,N'-(5-chloropentyl)-1,16-hexadecanediamine hydrochloride, or N, N'-dimethyl-N,N'-(4-chloropentyl)-1,16-hexadecanediamine hydrochloride.

19. (Amended) Pharmaceutical compositions, characterized in that they contain an effective quantity of at least one precursor as defined in [any one of] claim[s] 1[to 13], or at least one cyclized derivative corresponding to precursors of thiazolium of general formula (VI):




in which \underline{R}_b represents \underline{R}_1 or \underline{T} , \underline{T} representing the group of formula:




provided that Z does not represent a C1 to C8 alkyl radical, when R_c , R_d , R_l and R_2 represent a methyl radical.

R_d represents R_2 or P , P representing the group of formula



R_c represents R_3 or U , U representing the group of formula



R_1 , R_2 , R_3 and Z being as defined in claim 1,

it being understood that $R_b = T$, if $R_c = R_3$ and $R_d = R_2$; $R_d = P$, if $R_c = R_3$ and $R_b = R_1$; and $R_c = U$, if $R_b = R_1$ and $R_d = R_2$.

in combination with a pharmaceutically inert vehicle.

21. (Amended) Pharmaceutical compositions according to claim 19, [or medicaments manufactured according to claim 20,] characterized in this that they can be administered by oral route, by injectable route, or also by rectal route.